Manufactor:Bigbear Pharmaceutical Laos
Introduction:BRIGADX (Brigatinib) 90mg/180mg 28 Film-Coated Tablets - Tyrosine kinase inhibitor (TKI) targeting ALK/ROS1/EGFR mutations. - First-line or later treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC)
Indications:
Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in adults.
Dosage & Administration
Standard Dosage:
● Initial dose: 90 mg once daily for the first 7 days.
● After 7 days: If tolerated, increase to 180 mg once daily.
● Take with or without food.
● Swallow tablet whole with water—do not crush, split, or chew.
Missed Dose:
● If a dose is missed by ≤12 hours, take it immediately.
● If >12 hours late, skip the dose and resume the next scheduled dose.
● Never double dose.
Dose Adjustments:
● For severe side effects, may reduce to:
■ First reduction: 120 mg once daily
■ Second reduction: 90 mg once daily
■ Third reduction: 60 mg once daily
■ Discontinue if unable to tolerate 60 mg dose.
Precautions
1. Pulmonary Toxicity (ILD/Pneumonitis)
● Monitor for new/worsening cough, shortness of breath, fever.
● Interrupt treatment immediately if suspected; may require steroids.
2. Hypertension (High Blood Pressure)
● Check blood pressure after 1 week, then at least monthly.
● May require antihypertensive therapy.
3. Bradycardia (Slow Heart Rate)
● Monitor heart rate and blood pressure regularly.
● Avoid with other bradycardia-causing drugs (e.g., beta-blockers).
4. Elevated Pancreatic Enzymes
● Monitor amylase/lipase periodically.
5. Drug Interactions
● Avoid strong CYP3A inhibitors (e.g., ketoconazole)—may increase toxicity.
● Avoid strong CYP3A inducers (e.g., rifampin)—may reduce effectiveness.
Common Side Effects
· Nausea, diarrhea, vomiting
· Fatigue, headache
· Cough, shortness of breath
· Muscle/joint pain
· High blood pressure
Storage
Store at room temperature (20–25°C) in original packaging.
Note: ALK testing required before treatment.